Medicare Launches GLP-1 Bridge Program to Cover Anti-Obesity Drugs at $50 Per Month
The Centers for Medicare and Medicaid Services (CMS) has launched the Medicare GLP-1 Bridge demonstration program, providing eligible beneficiaries access to anti-obesity medications like semaglutide and tirzepatide for $50 per month through the end of 2027. This marks a significant policy shift, as federal law previously barred Medicare from covering obesity drugs despite spending billions on obesity-related conditions such as heart disease, diabetes, and kidney disease. The program addresses the fact that roughly two-thirds of Medicare beneficiaries are overweight or have obesity. Clinical evidence shows these drugs can lead to 15-20% weight loss and reduce risks of cardiovascular events, sleep apnea, and kidney disease. Critics cite a Congressional Budget Office estimate that broad coverage could increase federal deficits by $35 billion through 2034, but supporters argue this fails to capture long-term health savings and quality-of-life improvements.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection